GSK Gains FDA Approval for Breakthrough Cancer Immunotherapy

London, Tuesday, 20 October 2026.
GSK secured landmark US approval for its immunotherapy Jemperli, showing a 76% tumor-free rate in rectal cancer trial patients while trading at a discount compared to industry peers.